Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A S Coates

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2008
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancerG Gruber, B F Cole, M Castiglione-Gertsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1996
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study GroupG Marini, S Murray, A Goldhirsch, et al.
British Journal of Cancer|November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancerJ Bernhard, D Zahrieh, A S Coates, et al.
Breast Cancer Research and Treatment|December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 studyJ Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2005
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumorM Colleoni, S Li, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialN Zdenkowski, J F Forbes, F M Boyle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFTM M Regan, B A Walley, P A Francis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2008
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancerG Gruber, B F Cole, M Castiglione-Gertsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1996
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study GroupG Marini, S Murray, A Goldhirsch, et al.
British Journal of Cancer|November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancerJ Bernhard, D Zahrieh, A S Coates, et al.
Breast Cancer Research and Treatment|December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 studyJ Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2005
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumorM Colleoni, S Li, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialN Zdenkowski, J F Forbes, F M Boyle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFTM M Regan, B A Walley, P A Francis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.
Pageof 15